Optiver Holding’s Terns Pharmaceuticals TERN Stock Holding History

Optiver Holding’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-456	Closed	-$3.42K	–	2990
2025 Q3	$3.42K	Buy	+456	New	+$2.91K	﹤0.01%	2080

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CLGM

Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

Optiver Holding's TERN Position: Q4 2025 in Review

Optiver Holding sold out of Terns Pharmaceuticals (TERN) in Q4 2025, closing a stake of 456 shares — an estimated $3.42K sold.

Optiver Holding first reported a position in TERN in Q3 2025 and held it in 1 quarter. The position peaked at $3.42K in Q3 2025. 248 funds tracked by Wall St. Rank hold TERN as of Q4 2025.

Optiver Holding reported no remaining Terns Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Optiver Holding sold 456 Terns Pharmaceuticals shares in Q4 2025, an estimated $3.42K.
Optiver Holding first reported a position in Terns Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Optiver Holding's Terns Pharmaceuticals position peaked at $3.42K in Q3 2025.
248 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2025.

Based on Optiver Holding's 13F filing for Q4 2025, filed 17 Feb 2026.